Skip to Main Content

Paper Details

First-line pembrolizumab versus dabrafenib/trametinib treatment for BRAF V600-mutant advanced melanoma.
J Am Acad Dermatol
3
2022
BRAF, BRAF V600, BRAF V600 mutation, BRAF V600-, BRAF V600-mutant, BRAF V600-mutant melanoma, CD8, Melan-A, Melan-A-specific CD8 T, Melan-A-specific CD8 T cells, Pembrolizumab, advanced, advanced malignant melanoma, advanced melanoma, dabrafenib, melanoma, melanoma cells, mitogen-activated protein kinase kinase, patients, pembrolizumab, trametinib
Author NameAffiliation
Sung Tae KimSamsung Medical Center, Sungkyunkwan University School of Medicine
Sung Tae KimSamsung Medical Center, Sungkyunkwan University School of Medicine
Jeeyun LeeSamsung Medical Center, Sungkyunkwan University School of Medicine
  • 1 - 3

Datasets

Release 1.2